8-K: SpringWorks Therapeutics Stockholders Approve Merger with Merck KGaA

SpringWorks Therapeutics, Inc. announced that its stockholders overwhelmingly approved the proposed merger agreement with Merck KGaA, Darmstadt, Germany, at a special meeting held on June 26, 2025.

Summary

• SpringWorks Therapeutics, Inc. held a special meeting of stockholders on June 26, 2025, to vote on key proposals related to its merger with Merck KGaA, Darmstadt, Germany.
• As of the record date, May 27, 2025, there were 75,348,995 shares of SpringWorks Common Stock outstanding and entitled to vote.
• A quorum was present with 59,003,420 shares (78.31% of outstanding shares) represented in person or by proxy.
• Proposal 1, the Merger Agreement Proposal, was approved with 58,902,428 votes for, 89,192 votes against, and 11,800 abstentions.
• Proposal 2, the Adjournment Proposal, was not voted on as sufficient votes were secured for the Merger Agreement Proposal.
• Proposal 3, the Compensation Proposal (a non-binding advisory vote on executive compensation related to the merger), was approved with 54,818,866 votes for, 3,955,516 votes against, and 229,038 abstentions.

Sentiment

Score: 8

Explanation: The sentiment is highly positive as the key proposals, particularly the merger agreement, were overwhelmingly approved by stockholders, paving the way for the acquisition. This indicates successful progression of a major strategic event for the company.

Positives

• The Merger Agreement Proposal was overwhelmingly approved by stockholders, indicating strong support for the acquisition by Merck KGaA.
• The Compensation Proposal, related to executive compensation in connection with the merger, also received significant stockholder approval on a non-binding advisory basis.
• A high percentage of outstanding shares (78.31%) were represented at the Special Meeting, demonstrating strong stockholder engagement.

Risks

• The occurrence of any event, change, or circumstance that could lead to the termination of the Merger Agreement.
• The ability of the parties to satisfy or waive closing conditions for the proposed transaction, including regulatory approvals.
• Disruption to SpringWorks' business operations and relationships with employees, business partners, or governmental entities due to the proposed transaction.
• The response of competitors to the proposed transaction.
• Distraction of management's attention from ongoing business operations due to the proposed transaction.
• The ability of the parties to consummate the proposed transaction in a timely manner or at all.
• Significant costs associated with the proposed transaction.
• Potential litigation relating to the proposed transaction.
• Restrictions during the pendency of the proposed transaction that may impact SpringWorks' ability to pursue certain business opportunities.
• Risks related to the advancement of product candidates into, and successful completion of, preclinical studies and clinical trials.
• Risks and uncertainties related to regulatory application, review, and approval processes and compliance with applicable legal and regulatory requirements.
• General industry conditions and competition.
• General economic factors.

Future Outlook

The document highlights forward-looking statements regarding Merck KGaA's proposed acquisition of SpringWorks, including the ability of both parties to complete the transaction, satisfy closing conditions, and the expected timetable for completion. It also mentions the anticipated benefits of the acquisition and the potential effects on SpringWorks, while acknowledging the possibility of termination of the Merger Agreement. The success of SpringWorks' product candidates is also noted as a forward-looking aspect.

Management Comments

• The General Counsel and Secretary, Herschel S. Weinstein, signed the report on behalf of SpringWorks Therapeutics, Inc., confirming the results of the stockholder vote.

Industry Context

This announcement is specific to SpringWorks Therapeutics' corporate action of being acquired by Merck KGaA, a major pharmaceutical company. It reflects ongoing consolidation and strategic M&A activity within the biotechnology and pharmaceutical sectors, where larger entities acquire smaller, innovative companies to expand their pipelines and market presence.

Corporate Governance

Legal Proceedings

• Potential litigation relating to the proposed transaction is identified as a risk factor.

Stakeholder Impact

• Shareholders: Directly impacted by the merger, as their shares will be acquired by Merck KGaA, subject to the terms of the Merger Agreement.
• Employees: Potential effects of disruption from the proposed transaction and impact on relationships with employees are noted as risks.
• Business Partners: Potential effects of disruption from the proposed transaction and impact on relationships with other business partners are noted as risks.
• Governmental Entities: Potential effects of disruption from the proposed transaction and impact on relationships with governmental entities are noted as risks.
• Competitors: The response of competitors to the proposed transaction is identified as a risk.

Next Steps

• Completion of the proposed acquisition by Merck KGaA, Darmstadt, Germany, subject to the satisfaction of remaining closing conditions.
• Integration of SpringWorks Therapeutics into Merck KGaA as a wholly owned subsidiary.

Key Dates

Keywords

SpringWorks Therapeutics, SWTX, Merck KGaA, Merger Agreement, Stockholder Vote, Acquisition, SEC Filing, 8-K, Corporate Governance, Biotechnology, Pharmaceuticals